Technology | October 21, 2013
October 21, 2013 — Claron Technology announced U.S. Food and Drug Administration (FDA) clearance of NilRead zero-footprint viewer for the diagnostic interpretation of medical images. NilRead is the first universal, Web-based zero-footprint viewer supporting multi-monitor configurations.
A full-featured medical imaging viewer, NilRead enables diagnostic interpretation of medical images and related digital information on a variety of computers anytime, anywhere across the enterprise. It supports diagnostic viewing of all cleared digital imaging and communications in medicine (DICOM) imaging modalities on single or multi-monitor configurations. Running from a remote server, the viewer supports high-resolution, diagnostic-quality medical images and data formats with no software download and no compromise on performance.
The viewer also features customizable hanging protocols, prior-current comparison and extensive measurements. Its advanced visualization features include thin/thick slabs, MIP, volume rendering and positron emission tomography (PET)/computed tomography (CT) fusion. It delivers the highest levels of security and leaves no information on the viewing hardware when the session is complete.
“I have participated in the Claron Technology Clinical Study to assess NilRead image quality on a number of devices reviewing over 160 studies,” said Stephen Florence, M.D., managing partner, Credit Valley Imaging Associates and adjunct lecturer, Department of Medical Imaging, University of Toronto. “In addition to confirming the high quality display quality of NilRead, I have been able to quickly and effectively use the software on multiple devices with minimal instructions. I really appreciated the simplicity of the software, its usability and consistent graphical user interface across all the devices. I believe NilRead is going to be a very useful tool for Web-based diagnostic reads both inside and outside the hospital.”
For more information: www.clarontech.com
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now